Ablative Solutions Overview
- Founded
- 2011

- Status
- Private
- Employees
- 28

- Latest Deal Type
- Series D
- Latest Deal Amount
- $81M

- Investors
- 9
Ablative Solutions General Information
Description
Developer of a novel approach designed to address the significant unmet clinical need for systemic hypertension. The company's approach is a new catheter-based approach for percutaneous delivery of diagnostic and therapeutic agents into the area surrounding the peripheral blood vessels, enabling clinicians to alter the overactive signaling process and reduce patients' blood pressure.
Contact Information
- 2479 East Bayshore Road
- Kalamazoo, MI
- United States
Ablative Solutions Timeline
Ablative Solutions Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Later Stage VC (Series D) | 03-Jan-2019 | $81M | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
4. Later Stage VC (Series C) | 01-Mar-2017 | 000.00 | 000.00 | 0000 | Completed | Clinical Trials - Phase 3 |
3. Early Stage VC (Series B) | 12-Jan-2015 | 000.00 | 000.00 | 000.00 | Completed | Startup |
2. Early Stage VC (Series A) | 19-Jun-2012 | $5.37M | $12.3M | 000.00 | Completed | Startup |
1. Early Stage VC | 10-Feb-2012 | $6.92M | $6.92M | Completed | Startup |
Ablative Solutions Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series D2 | 00,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
Series D1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series C | 0,000,000 | 00.000000 | 00 | 00.0 | 00.00 | 00 | 00.0 | 00.000 |
Series B | 2,805,392 | $0.001000 | 8% | $5.57 | $8.36 | 1x | $5.57 | 5.07% |
Series A | 1,287,757 | $0.001000 | 8% | $3.85 | $5.78 | 1x | $2.3 | 3.96% |
Ablative Solutions Comparisons
Industry
00000 00
00000 00
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAblative Solutions Competitors (4)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Recor Medical | Formerly VC-backed | Palo Alto, CA | 00 | 000.00 | 000000&0 | 000.00 |
00000 0000000 | Formerly VC-backed | Sunnyvale, CA | 00 | 000.00 | 000000&0 | 000.00 |
000000 00000000 | Angel-Backed | Menlo Park, CA | 0 | 00.00 | 0000000000 | 00.00 |
000000000 | Corporation | Minneapolis, MN | 00000 | 00000000 |
Ablative Solutions Executive Team (12)
Ablative Solutions Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
Andrew Tochterman | Ablative Solutions | Board Member | 000 0000 |
Dale Grogan | Michigan Accelerator Fund 1 | Board Member | 000 0000 |
David Fischell Ph.D | Self | Co-Founder & Board Member | 000 0000 |
Geoff Pardo | Gilde Healthcare Partners | Board Member | 000 0000 |
Kathryn Rumrill | Ablative Solutions | President, Chief Executive Officer & Board Member | 000 0000 |
Ablative Solutions Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAblative Solutions Investors (9)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Gilde Healthcare Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Trout Creek Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Dempsey Ventures | PE/Buyout | Minority | 000 0000 | 000000 0 | |
GlobalLink1 Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
BioStar Capital | Venture Capital | Minority | 000 0000 | 000000 0 |